Lidds AB
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
LIDDS | ST
Overview
Corporate Details
- ISIN(s):
- SE0001958612
- LEI:
- 549300YYW8B918K7UN72
- Country:
- Sweden
- Address:
- Box 12040, 112 40 Stockholm
- Website:
- https://liddspharma.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Lidds AB is a pharmaceutical company that develops oncology treatments based on its proprietary NanoZolid® drug delivery technology. The NanoZolid® platform enables local, controlled, and sustained release of drugs, aiming to increase therapeutic efficacy at the tumor site while reducing systemic side effects. The technology involves injecting a drug formulation that forms a solid depot, which releases the active substance over a prolonged period before being fully absorbed by the body. Lidds' pipeline includes projects such as Liproca Depot for prostate cancer, Nanodotax, and Nanoimod. The company's strategy focuses on reformulating existing drugs to lower development costs and enhance market potential. The technology is validated through clinical trials and strategic partnerships, including agreements with Johnson & Johnson Enterprise Innovation and Puheng Pharma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lidds AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lidds AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lidds AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-02-14 | Anders Månsson | Other | Buy | 100,000 | 140,000.00 SEK |
| 2023-02-10 | Matthew Lindon | Other | Buy | 71,428 | 99,999.20 SEK |
| 2023-02-09 | Daniel Lifveredson | Other | Other | 150,000 | 210,000.00 SEK |
| 2022-12-16 | Daniel Lifveredson | Other | Sell | 435,254 | 826,982.60 SEK |
| 2022-12-16 | Daniel Lifveredson | Other | Buy | 435,254 | 826,982.60 SEK |
| 2022-06-02 | Galba Holding AB | Other | Buy | 750,000 | 4,500,000.00 SEK |
| 2022-03-08 | Jan Törnell | Other | Buy | 5,000 | 32,500.00 SEK |
| 2021-06-30 | Nina Herne | Other | Other | 100,000 | 116,000.00 SEK |
| 2021-06-03 | Daniel Lifveredson | Other | Buy | 435,254 | 4,483,116.20 SEK |
| 2021-05-31 | Maria Forss | Other | Buy | 2,300 | 29,992.00 SEK |
Peer Companies
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
